Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
18.33
-1.19 (-6.10%)
At close: May 9, 2025, 4:00 PM
18.68
+0.35 (1.91%)
After-hours: May 9, 2025, 5:01 PM EDT
Celldex Therapeutics Employees
Celldex Therapeutics had 186 employees as of December 31, 2024. The number of employees increased by 26 or 16.25% compared to the previous year.
Employees
186
Change (1Y)
26
Growth (1Y)
16.25%
Revenue / Employee
$40,640
Profits / Employee
-$961,565
Market Cap
1.22B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CLDX News
- 2 days ago - Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 days ago - Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease - GlobeNewsWire
- 2 months ago - Celldex Therapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025 - GlobeNewsWire
- 2 months ago - Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025 - GlobeNewsWire
- 2 months ago - Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 months ago - Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis - GlobeNewsWire
- 6 months ago - Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases - GlobeNewsWire